Nexavar



Indications and Reactions:

Role Indications Reactions
Primary
Hepatic Neoplasm Malignant 30.5%
Renal Cell Carcinoma 11.5%
Drug Use For Unknown Indication 10.8%
Hypertension 7.2%
Renal Cell Carcinoma Stage Iv 5.8%
Prophylaxis 5.8%
Renal Cell Carcinoma Stage Unspecified 5.4%
Hepatocellular Carcinoma 3.4%
Metastatic Renal Cell Carcinoma 3.0%
Pain 2.4%
Diabetes Mellitus 1.9%
Constipation 1.8%
Hepatic Cancer 1.7%
Product Used For Unknown Indication 1.5%
Insomnia 1.5%
Gastritis Prophylaxis 1.3%
Renal Cancer 1.3%
Thyroid Cancer 1.1%
Diarrhoea 1.0%
Hepatic Cirrhosis 0.9%
Palmar-plantar Erythrodysaesthesia Syndrome 16.1%
Rash 12.3%
Weight Decreased 7.0%
Vomiting 6.7%
Pyrexia 6.5%
Death 5.6%
Stomatitis 5.2%
Hepatic Function Abnormal 5.0%
Diarrhoea 4.3%
Hepatic Encephalopathy 4.1%
Platelet Count Decreased 3.7%
Hepatic Neoplasm Malignant 3.0%
Renal Cell Carcinoma 2.9%
Hypertension 2.9%
White Blood Cell Count Decreased 2.7%
Hepatic Failure 2.7%
Nausea 2.6%
Rash Generalised 2.3%
Pain In Extremity 2.2%
Fatigue 2.1%
Secondary
Hepatic Neoplasm Malignant 24.3%
Renal Cell Carcinoma 13.4%
Prophylaxis 9.2%
Hypertension 8.3%
Renal Cell Carcinoma Stage Iv 7.6%
Hepatocellular Carcinoma 5.4%
Drug Use For Unknown Indication 4.6%
Pain 4.6%
Constipation 3.1%
Hepatic Cancer 2.8%
Insomnia 2.4%
Metastatic Renal Cell Carcinoma 2.0%
Diabetes Mellitus 1.9%
Nausea 1.8%
Gastritis Prophylaxis 1.7%
Renal Cell Carcinoma Stage Unspecified 1.6%
Product Used For Unknown Indication 1.5%
Prophylaxis Against Gastrointestinal Ulcer 1.4%
Diarrhoea 1.3%
Thyroid Cancer 1.2%
Palmar-plantar Erythrodysaesthesia Syndrome 22.6%
Rash 10.4%
Vomiting 7.7%
Weight Decreased 7.6%
Pyrexia 7.2%
Stomatitis 7.1%
White Blood Cell Count Decreased 5.6%
Hepatic Function Abnormal 4.8%
Platelet Count Decreased 4.7%
Diarrhoea 2.9%
Renal Cell Carcinoma 2.4%
Hepatic Encephalopathy 2.4%
Malaise 2.2%
Nausea 2.2%
Hypertension 1.9%
Hepatic Neoplasm Malignant 1.9%
Skin Exfoliation 1.7%
Thrombocytopenia 1.7%
Pancreatic Enzymes Increased 1.5%
Pleural Effusion 1.5%
Concomitant
Metastatic Renal Cell Carcinoma 24.9%
Metastases To Bone 7.9%
Product Used For Unknown Indication 7.9%
Nuclear Magnetic Resonance Imaging 7.3%
Pain 5.0%
Prophylaxis 4.8%
Cancer Pain 4.6%
Drug Use For Unknown Indication 4.4%
Liver Transplant 4.0%
Neoplasm Malignant 3.7%
Renal Cancer 3.7%
Renal Cell Carcinoma 3.7%
Hepatic Neoplasm Malignant 3.3%
Hypertension 2.5%
Neoplasm 2.3%
Constipation 2.1%
Hepatitis B 2.1%
Pulmonary Arterial Hypertension 2.1%
Diabetes Mellitus 1.9%
Nausea 1.9%
Death 13.5%
Skin Fibrosis 8.3%
Pain 7.3%
Wound Dehiscence 7.3%
Disease Progression 6.3%
Neoplasm Malignant 5.2%
Visual Acuity Reduced 5.2%
Weight Decreased 5.2%
Diarrhoea 4.2%
Rash 4.2%
Sepsis 4.2%
Toxic Epidermal Necrolysis 4.2%
Constipation 3.1%
Dermatitis Bullous 3.1%
Hyperkalaemia 3.1%
Joint Swelling 3.1%
Neoplasm Progression 3.1%
Off Label Use 3.1%
Pain In Jaw 3.1%
Pulmonary Fibrosis 3.1%
Interacting
Hiv Infection 30.4%
Tuberculosis 24.3%
Hepatic Neoplasm Malignant 14.2%
Prophylaxis Against Gastrointestinal Ulcer 8.1%
Renal Cell Carcinoma Stage Iv 8.1%
Product Used For Unknown Indication 3.4%
Renal Cell Carcinoma 3.4%
Atrial Fibrillation 1.4%
Hepatitis B 1.4%
Hepatocellular Carcinoma 1.4%
Carcinoid Tumour Of The Gastrointestinal Tract 0.7%
Chronic Myeloid Leukaemia 0.7%
Hepatic Cancer 0.7%
Metastases To Bone 0.7%
Palliative Care 0.7%
Type 2 Diabetes Mellitus 0.7%
Tuberculosis 36.4%
Blister 27.3%
Tongue Discolouration 9.1%
Therapeutic Agent Toxicity 6.1%
Alanine Aminotransferase Increased 3.0%
Aspartate Aminotransferase Increased 3.0%
Erysipelas 3.0%
Hepatotoxicity 3.0%
Portal Vein Thrombosis 3.0%
Rectal Haemorrhage 3.0%
Thrombocytopenia 3.0%